Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Cirazoline is an α1-adrenergic receptor (α1-AR) agonist (Kis = 120, 960, and 660 nM for recombinant α1A-, α1B-, and α1D-ARs, respectively, in CHO cell membranes).1 It acts as a full agonist at α1A- and a partial agonist at α1B- and α1D-ARs in vitro (EC50s = 70.7, 79.4, and 239.8 nM, respectively). It also acts as an antagonist at α2-ARs with a pA2 value of 7.56 to inhibit the norepinephrine-induced twitch response in isolated pig ileum.2 Cirazoline (0.01-1 µg/kg) decreases blood pressure when administered via microinjection to the nucleus reticularis lateralis (NRL) of anesthetized normotensive cats.3 It enhances spatial memory and reduces depressive- and anxiety-like behavior in mice when administered at a concentration of 10 mg/L in drinking water for 2-9 months.4 It also enhances performance in the variable delayed response task in aged rhesus monkeys at high doses of 1-10 µg/kg but impairs performance at lower doses of 0.01-1 µg/kg.5
WARNING This product is not for human or veterinary use.
1. Selectivity of the imidazoline α-
2. Receptor interactions of imidazolines: α-
3. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 2301(1), 232-236 (1984).
4. Long-
5. The alpha-